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Abstract 
Background: Ventilator-associated pneumonia (VAP) is common and costly. In a recent randomized 
controlled trial, the Venner-PneuX (VPX) endotracheal tube system was found to be superior to 
standard endotracheal tubes (SET) in preventing VAP. However, VPX is considerably more expensive. 
We evaluated the costs and benefits of VPX to determine whether replacing SET with VPX is a cost-
effective option for intensive care units.  
Methods: We developed a decision analytic model to compare intubation with VPX or SET for patients 
requiring mechanical ventilation post cardiac surgery. The model was populated with existing evidence 
on costs, effectiveness and quality of life. Cost-effectiveness and cost-utility analyses were conducted 
from an NHS hospital perspective. Uncertainty was assessed through deterministic and probabilistic 
sensitivity analyses.  
Results: Compared to SET, VPX is associated with an expected cost saving of £738 per patient. VPX 
led to a small increase in quality-adjusted life years (QALYs), indicating that the device is overall less 
costly and more effective than SET. The probability of VPX being cost-effective at £30,000 per QALY 
is 97%. VPX would cease to be cost-effective if (i) it led to a risk reduction smaller than 0.02 compared 
to SET, (ii) the acquisition cost of VPX was as high as £890 or, (iii) the cost of treating a case of VAP 
was lower than £1,450.  
Conclusions: VPX resulted in improved outcomes and savings which far offset the cost of the device, 
suggesting that replacing SET with VPX is overall beneficial. Findings were robust to extreme values 
of key parameters.  
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Introduction 
Between 8% and 28% of all patients receiving mechanical ventilation develop ventilator-associated 
pneumonia (VAP), a common infection caused by pathogens colonizing a patient’s upper aero-digestive 
tract (1). VAP is linked to higher mortality, with critically ill patients who develop VAP being twice as 
likely to die (2), and substantial use of health care resources, chiefly due to prolonged stay and additional 
diagnostic and therapeutic interventions (3-5). Existing studies report the additional health care cost 
attributed to VAP to be between $10,000 (£7,520) and $60,000 (£45,110) per case (2, 4, 6). 
VAP is caused by contaminated aero-digestive secretions pooling in the subglottic space above the 
inflated cuff of an endotracheal tube (ET). The cuff aims to provide an airtight seal to facilitate 
maintenance of positive end expiratory pressure; however, micro-folds developing in the inflated cuff 
allow the contaminated subglottic secretions to micro-aspirate past the cuff into the lower respiratory 
tract (7, 8). Given this, there has been considerable interest in ETs that retain adequate cuff pressure 
against the tracheal wall (9).  
The significant health and economic burden of VAP has led to increasing interest in the development 
and use of interventions aimed at preventing its occurrence (10, 11). Venner-PneuX (VPX) is an 
endotracheal system that aims to monitor, control and maintain a safe inflation volume and pressure 
(30cm H2O) within the cuff in order to reduce the risk of tracheal injury.  
 In a recent randomized controlled trial funded by the Department of Health in the UK (ISRCTN 
45757289), VPX was associated with a significant reduction of VAP as compared to a standard, widely 
used endotracheal tube (SET) (odds ratio 0.45, P = 0.03) (12). 
However, in an environment of constrained resources, a rigorous economic assessment of VPX is 
necessary prior to introducing the device in the intensive care setting. As VPX costs considerably more 
than standard tubes (an additional £145 per tube), providers of critical care services need to know 
whether, and to what extent, the effectiveness of VPX in preventing VAP compensates for the higher 
acquisition cost of the device. The need for an economic analysis has been highlighted by the National 
5 
Institute for Health and Care Excellence (NICE) in the UK in a recent report, which highlights the 
potential of VPX to reduce intensive care unit (ICU) and hospital stay but stresses the lack of evidence 
on its cost-effectiveness (13). 
We undertook an economic evaluation to determine the additional costs (device acquisition cost, overall 
treatment cost) and benefits (number of VAP cases prevented, quality-adjusted life years (QALYs) 
gained) associated with VPX in comparison to SET for patients requiring mechanical ventilation in a 
critical care setting.  
Materials and Methods 
We built a decision model to evaluate the expected costs and benefits associated with VPX and SET. 
The evaluation was carried out from the perspective of NHS secondary health care service providers. 
The target population comprised hospitalised patients who required intubation after major cardiac 
surgery. Given the acute nature of VAP and the focus on secondary care providers, the time horizon 
was set at 28 days after surgery. Monetary values were expressed in 2016 UK sterling (£1=$1.33) (14). 
Model structure  
The expected costs and consequences of VPX and SET were assessed through a simple decision tree, 
the graphical representation of which can be seen in Figure 1. Paths (branches) in the model represent 
eventualities following the choice of endotracheal tube for a patient who has undergone cardiac surgery 
and requires post-operative mechanical ventilation. Analyses were carried out in STATA (StataCorp, 
Release 12. College Station, TX, US) and Microsoft Excel (Microsoft, Version 2010, Redmont, WA, 
US).  
Model inputs 
Inputs used in the model are detailed in Supplemental Material 1. Key information on the effectiveness 
of VPX in preventing VAP was obtained from a clinical trial comparing VPX against SET (ISRCTN 
45757289). A detailed description of the trial and its findings is given in Gopal et al. (12). Briefly, the 
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trial randomized 240 consenting patients scheduled to undergo cardiac surgery to either SET (n=120) 
or VPX (n=120) and found a lower incidence of VAP in the VPX group compared to SET (10.8% vs. 
21%, odds ratio: 0.45, p=0.03), although there was no statistically significant difference in ICU stay 
and in-hospital mortality. The obtained data were used to establish the risk of developing VAP 
associated with the use of each tube, the absolute risk difference between VPX and SET and the 
probability that a patient will contract VAP with each of the compared options (P(VAP)VPX and 
P(VAP)SET, respectively). 
Costs associated with each treatment were estimated according to the acquisition cost of VPX and SET 
and the estimated cost of care provided to patients with and without VAP. The acquisition cost of VPX 
(AqCvpx in the model) was obtained from the UK distributor of the device (Qualitech Healthcare 
Limited, Maidenhead, UK). The mean costs associated with treatment of patients who did and did not 
develop VAP (CVAP and CnoVAP, respectively) were obtained from a published propensity-matched study 
of prospectively collected resource use data drawn from the same hospital as the study that provided 
estimates of the effectiveness of VPX and SET (12). Details of this study can be found in Luckraz et al. 
(15). In brief, all patients undergoing cardiac surgery at the Heart & Lung Centre, New Cross Hospital 
during the period of April 2011 to December 2014 were initially selected (n=3416). Patients who were 
diagnosed to have developed definite VAP using the CDC definition (16) and the Hospitals in Europe 
Link for Infection Control through Surveillance (HELICS) clinical criteria (17) were included in the 
VAP group (n=338) and were matched to patients who did not develop VAP using propensity scores 
generated from a logistic regression model. Ethical approval for this study was provided by the Ethical 
Committee West of Scotland Research Ethic Service (reference: 15/WS/0142) in July 2015. 
Anonymised information on each patient’s inpatient stay and use of health care resources was extracted 
from routinely collected Healthcare Resource Group (HRG) codes available from the hospital’s records. 
HRG codes are standard clinical groupings which detail the amount and composition of health care 
resources that a patient with a particular condition or diagnosis is expected to use (18). Given the short 
time horizon of this analysis, neither costs nor benefits were discounted. 
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The analysis was extended to assess the effect of VPX and SET in terms of QALYs, a measure that 
combines time spent in a particular health state with estimates of the preference-based health related 
quality of life (utility) associated with the state. QALYs associated with and without contraction of 
VAP (QALYVAP and QALYnoVAP, respectively) were calculated over 28 days as the sum of two 
components: the product of time and utility associated with stay in the ICU, and the product of time and 
utility for stay in ward: 
𝑄𝐴𝐿𝑌𝑖 = 𝑈𝐼𝐶𝑈 × 𝑇𝑖,𝐼𝐶𝑈 + 𝑈𝑊𝑎𝑟𝑑 × 𝑇𝑖,𝑊𝑎𝑟𝑑 
where i represents the existence or absence of VAP (i=VAP, noVAP), U represents the utility associated 
with stay in ICU or ward, and T represents the average time (in days) that patients are expected to spend 
in ICU and ward. Estimates for the time spent in ICU and ward for patients with and without VAP were 
obtained from anonymised patient-level data collected in the same matched cohort study that 
contributed data on resource use. As in Edwards et al. (19), it was assumed that an intubated patient in 
critical care would experience a level of quality of life comparable to being unconscious. A quality of 
life value for a patient recovering in ward was taken from Eddleston et al. (20). Alternative values were 
used in sensitivity analyses.  
Cost-effectiveness and cost-utility analyses 
Cost-effectiveness and cost-utility analyses were conducted to compare VPX against SET through the 
developed model. Results were obtained by carrying out standard roll-back calculations (21). The total 
cost for each option (i.e. VPX or SET) comprises the acquisition cost of the technology plus the 
expected cost associated with each possible eventuality (i.e. developing or not developing VAP). The 
latter is calculated as the cost of the event of interest (VAP) weighted by the probability of the event 
occurring under each option (P(VAP)VPX and P(VAP)SET for VPX and SET, respectively). 
Findings from the cost-effectiveness analysis are expressed as i) cost per case of VAP avoided and ii) 
total net benefit. The cost per case of VAP avoided represents the additional intubation-related 
expenditures for avoiding a case of VAP. The total net benefit extends these findings by accounting for 
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the monetary value of avoiding a case of VAP. This metric reflects the difference between the overall 
costs of VPX and SET, when these costs include the outlay for treating a case of VAP.  
𝑇𝑁𝐵(𝑆𝐸𝑇 𝑣𝑠 𝑉𝑃𝑋) =  (𝐴𝑞𝐶𝑆𝐸𝑇 + 𝑇𝑜𝑡𝐶𝑜𝑠𝑡𝑆𝐸𝑇)  − (𝐴𝑞𝐶𝑉𝑃𝑋 + 𝑇𝑜𝑡𝐶𝑜𝑠𝑡𝑉𝑃𝑋) 
where AqCSET and AqCVPX stand for the acquisition cost of SET and VPX respectively, and TotCostSET 
and TotCostVPX represent the expected cost of VAP for patients intubated with SET and VPX 
respectively, given the probability of contracting VAP associated with each tube.  
Results of the cost-utility analysis reflect the additional cost (or cost saving) associated with a gain of 
an additional QALY. Findings are given as point-estimate values and are plotted in cost-effectiveness 
acceptability curves (CEACs) (22, 23). CEACs show the probability of VPX being cost-effective across 
a range of possible monetary values representing decision makers (or society’s) the willingness to pay 
to for a unit of outcome—here, a case of VAP avoided and an additional QALY. 
Sensitivity analysis 
In line with recommendations (24, 25), uncertainty in the model was assessed through probabilistic and 
deterministic sensitivity analyses. The former involved assigning probability distributions to key 
parameters and carrying out a large number of Monte Carlo simulations (26). In each of these 
simulations, values were drawn at random from the specified distributions of uncertain parameters. 
Each set of drawn values was entered in the model and results were re-calculated to give 5,000 estimates 
of the costs and effects associated with each treatment (27). Parameters assigned probability 
distributions included the probability of a patient developing VAP when intubated with VPX and SET, 
the quality of life in ICU and ward and the cost associated with patients who did and did not develop 
VAP. 
In addition to probabilistic sensitivity analysis, deterministic analyses were carried out to assess the 
robustness of the results to alternative values of key parameters. Threshold analysis was also undertaken 
to determine the values of these parameters (i.e. the effectiveness of VPX and SET, the acquisition cost 
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of VPX and SET and the additional cost of VAP) above and below which conclusions about the cost-
effectiveness of the compared options change.  
Results 
Base case cost-effectiveness and cost-utility results 
The additional VPX acquisition cost per VAP case avoided is £1,450. This value reflects the extra cost 
of intubating 10 patients with VPX as opposed to SET in order to prevent one case of VAP. Preventing 
a case of VAP is associated with a saving of £8,829, thus, subtracting this value from the additional 
cost of VPX, one can obtain an estimate of the total net benefit associated with VPX. A hospital would 
need to invest £1,450 in order to offer VPX to 10 patients, but this investment would result in an 
additional case of VAP avoided, which would save £8,829. This results in a total net benefit of £7,379 
for 10 patients, or £738 per patient (Table 1). 
In the cost-utility analysis, VPX was associated with cost savings due to avoided VAP and a greater 
number of QALYs due to reduced stay in ICU, suggesting that the device dominates SET (i.e. is less 
costly and more effective than SET). As VPX is a dominant option, calculating an ICER for the 
particular comparison is not necessary (21).  
Sensitivity analysis results 
Uncertainty around the results was explored through probabilistic, deterministic and threshold 
sensitivity analyses.   
Results of deterministic sensitivity analyses showed that, for all alternative values of uncertain 
parameters, VPX was overall less costly and resulted in greater numbers of QALYs. The total net 
benefit for different values and assumptions ranged from £421 to £2,390 (see Supplemental Material 
2).  
The outputs of probabilistic sensitivity analysis for the cost-effectiveness and the cost-utility analyses 
are depicted in cost-effectiveness planes (Figures 2 and 3) and are plotted in CEACs (Figure 4). The 
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probability of VPX being cost-effective at a range of possible values of a provider’s willingness to pay 
to avoid a case of VAP is 18% at £1,000, it increases to 72% at £2,000 and it reaches 97% at £10,000. 
In terms of cost per QALY, the probability of VPX being cost-effective is 96% at willingness to pay 
values between £0 and £30,000 per QALY and it rises slowly to 97% for values over £80,000 per QALY 
(not shown here).  
Threshold analysis sought to explore the cut-off values above and below which VPX would cease to be 
cost-effective. Detailed results can be found in Supplemental Material 3. Assuming that there is no 
difference in the rate of VAP for VPX and SET, the adoption of VPX would result in a net cost of £145 
per patient, equal to the additional acquisition cost of VPX. For any absolute risk reduction values over 
0.02, the cost savings would exceed the additional cost of VPX and result in net benefit. Holding the 
absolute risk reduction at its base case value, if the additional cost of VAP was as low as £2,000, VPX 
would still be associated with a total net benefit of about £55 per patient. If this cost was £20,000, the 
total net benefit would exceed £1,800 per eligible patient. Lastly, if the device’s acquisition cost was 
three times less than its current price (i.e. £50, as opposed to £150, the total net benefit per patient would 
be approximately £840). Conversely, a cost of VPX three times as high would result in a total net benefit 
of about £440. VPX would cease to result in a net benefit if its acquisition cost was greater than £890. 
Comment 
Tackling health care-associated infections, including VAP, is an important policy objective for health 
systems around the world (28-30). Different prevention measures are available, but it is important to 
ensure that replacing standard care with a particular technology represents an efficient use of scarce 
resources.  
Our analysis shows that the additional cost of adopting VPX is £1,450 per case of VAP avoided. This 
cost is well below the savings resulting from avoiding the need to treat a case of VAP. The total net 
benefit, that is, the cost savings associated with VPX minus the additional acquisition cost of VPX, is 
£738 per eligible patient. VPX would still lead to cost savings which would cover its acquisition cost 
even if (i) the acquisition cost of VPX was as high as £890 (about 6 times as high as the reference 
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acquisition cost), (ii) the absolute risk reduction associated with VPX over SET is not less than 0.02, or 
(iii) the savings from preventing a case of VAP were as low as £1,450, far below the observed values 
used in this analysis or other values cited in the literature (2, 5, 6, 31). 
Our work presents certain strengths. We developed a simple, parsimonious model which can be easily 
updated should newer data emerge in the future. The model was populated with available with 
effectiveness estimates from a randomized controlled trial of VPX, while costs were calculated on the 
basis of patient-level data from a matched cohort in the same UK hospital, using actual HRG tariffs. In 
the UK, HRG codes are recorded for each patient and the resulting patient-level data is used to calculate 
payments to National Health Service providers (32). Uncertainty was explored via probabilistic and 
deterministic sensitivity analyses, and threshold analysis was carried out to evaluate the possible impact 
of different scenarios on the results (24). 
Despite this, findings are subject to certain uncertainties. First, the fact that evidence comes from a 
single randomized trial, the LoVAP study, adds a layer of uncertainty. To the authors’ best knowledge, 
this trial is the only source of estimates of the effectiveness of VPX as compared to SET which are 
relevant to the question we set out to answer. This study involved 120 patients per arm, on the basis of 
a standard sample size calculations for the primary outcome of VAP occurrence. Should further rigorous 
data on the effectiveness of VPX and SET in preventing VAP become available in the future, this can 
be incorporated in our model. Secondly, there is a lack of robust estimates of the health-related quality 
of life associated with patients in critical care settings, largely due to practical and ethical difficulties in 
collecting patient-reported data (33). In line with existing studies, we assumed that quality of life will 
be higher (i.e. better) when a patient is recovering in ward than when she/he is intubated in ICU. Thus, 
the total QALYs associated with VPX and SET are largely driven by the amount of time spent in ICU 
or ward and are directly related to each option’s effectiveness in preventing VAP and further stay in 
ICU. This also applies to costs: estimates of the cost of developing and not developing VAP obtained 
from a matched study were applicable to both VPX and SET, with the total cost, as expected, depending 
on the likelihood of a patient developing VAP with either VAP or SET intubation. Drawing on some of 
the authors’ experience with VPX, we would recommended that, unless clinically indicated, the 
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endotracheal tube (ETT) used at the time of intubation (initial anesthesia) for cardiac surgery should 
not be changed to another ETT, as this change of ETT in itself can predispose to VAP. Hence for the 
benefit of VPX to be gained, it is preferable that the device is used from the time of the initial intubation. 
To the authors’ best knowledge, this is the first economic evaluation of the Venner PneuX endotracheal 
tube against a standard tube. In a recent study, Branch-Elliman and colleagues (34) evaluated the cost-
effectiveness of different VAP preventing strategies. Lack of data from a head-to-head comparison of 
the evaluated treatments meant that the authors had to combine information from different sources. The 
authors found subglottic endotracheal tubes to be cost-effective at a willingness-to-pay threshold of 
$50,000 to $100,000 (£37,590 to £75,190). Although this analysis provides useful insights, the authors 
acknowledge that key inputs were drawn from a study published almost 15 years ago, in 2002. Our 
study addresses this issue by using evidence of the cost of treating patients with and without VAP from 
the same study. 
Conclusions 
Overall, findings suggest that the benefits of VPX exceed its additional cost, resulting in a total net 
benefit of £738 per patient. VPX resulted in lower costs and a gain in QALYs. The results are robust to 
extreme values of the key parameters in the analysis.  
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Table 1. Results of cost-effectiveness and cost-utility analyses 
Summary 
table 
Total Cost 
Total 
QALYs 
Cost per case 
avoided (VPX vs 
SET) 
Total Net 
Benefit (per 
patient, VPX vs 
SET) 
ICER (VPX 
vs SET) 
VPX £7,401 0.025 
£1,450 £738 
Cost savings 
and QALYs 
gained SET £8,139 
0.024 
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Figure legends 
 
Figure 1. Structure of the decision model. 
Figure 2. Cost-effectiveness plane showing 5000 paired estimates of the difference in cost and 
difference in number of cases of VAP avoided (VPX vs SET) 
Figure 3. Cost-effectiveness plane showing 5000 paired estimates of the difference in cost and 
difference in QALYs (VPX vs SET) 
Figure 4. Cost-effectiveness acceptability curves showing the probability of VPX being cost-effective. 
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Figure 1. Structure of the decision model. 
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Figure 2. Cost-effectiveness plane showing 5000 paired estimates of the difference in cost and difference in number of cases of VAP avoided (VPX vs SET) 
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Figure 3. Cost-effectiveness plane showing 5000 paired estimates of the difference in cost and difference in QALYs (VPX vs SET).  
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Figure 4. Cost-effectiveness acceptability curves showing the probability of VPX being cost-effective. 
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Supplemental Material 1. Model inputs and associated probability distributions. 
Parameter Point estimate value Probability distribution 
Source/comment 
Costs 
VPX acquisition cost (AqCVPX) 
£150 Gamma (100, 1.5) Value taken from distributor and NICE (13).  
Distribution fitted assuming a standard deviation of 1/10 of 
the acquisition cost value. 
Standard endotracheal tube (Portex tracheal 
tube) acquisition cost (AqCSET) 
£5 Gamma (100, 0.05) Value taken from the procurement department of the Royal 
Wolverhampton NHS Trust.  
Distribution fitted assuming a standard deviation of 1/10 of 
the acquisition cost value. 
Mean NHS treatment cost for a patient who 
developed VAP post cardiac surgery (CVAP) 
£15,124 Gamma (0.86, 7317) Values obtained from propensity matched cohorts who did 
and did not develop VAP at the Royal Wolverhampton NHS 
Trust.  
Distribution fitted to observed mean and standard deviation 
values. 
Mean NHS treatment cost for a patient who 
did not developed VAP post cardiac surgery 
(CnoVAP) 
£6,295 Gamma (0.634, 23852) 
Effectiveness and quality of life 
Probability of developing VAP while 
intubated with VPX (P(VAP)VPX 
0.11 Beta (13, 107) Point estimates obtained from Gopal et al. (12).  
Distribution fitted to reported values. 
Probability of developing VAP while 
intubated with SET (P(VAP)SET 
0.21 Beta (25, 95) 
Preference-based quality of life (utility) 
while intubated in ICU 
-0.402 Gamma (7.18 
0.056) 
Point estimate values calculated on the basis of relevant 
literature (18, 19).  
 
Distribution fitted to reported values. Preference-based quality of life (utility) 
while recovering on ward 
0.726 Gamma (132.45, 0.013) 
VPX: Venner-PneuX; VAP: ventilator-associated pneumonia; SET: standard endotracheal tube; ICU: intensive care unit. 
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Supplemental Material 2. Results of deterministic sensitivity analyses 
Alternative values Parameter 
Total Net 
Benefit (VPX vs 
SET) 
Difference 
in Costs 
Difference 
in QALYs 
Cost per QALY Source/comment 
Additional cost of 
VAP 
 
£5,660 £421 £421 0.0007 VPX less costly 
and more 
effective. 
Published literature (2) 
£7,220 £577 £577 0.0007 VPX less costly 
and more 
effective 
Published literature (4) 
£17,261 £1,581 £1,581 0.0007 VPX less costly 
and more 
effective 
Published literature (31) 
£25,351 £2,390 £2,390 0.0007 VPX less costly 
and more 
effective 
Published literature (6) 
Quality of life in 
ICU and ward 
ICU: 0.3 
Ward: 0.5 
£738 £738 0.0001 VPX less costly 
and more 
effective 
Published literature (35) 
ICU: -0.166 
Ward: 0.516 
£738 £738 0.0004 VPX less costly 
and more 
effective 
Based on the EQ-5D valuation of a health state 
with the following attributes:  
 
In ICU: 
Mobility: I am confined to bed; Self-care: I'm 
24 
unable to wash or dress myself; Usual activities: 
I am unable to perform my usual activities; 
Pain/discomfort: I have moderate pain or 
discomfort; Anxiety/Depression: I am 
moderately anxious/depressed). 
 
In ward:  
Mobility: I have some problems in walking 
about; Self-care: I have some problems washing 
or dressing myself; Usual activities: I have some 
problems with performing my usual activities; 
Pain/discomfort: I have moderate pain or 
discomfort; Anxiety/Depression: I am 
moderately anxious/depressed). 
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Supplementary Material 3 
Table 1. Total net benefit for different values of absolute risk reduction of VAP 
Table 2. Total net benefit for different values of the additional cost of treating VAP 
Table 3. Total net benefit for different values of the acquisition cost of VPX 
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SDC Table 1. Total net benefit for different values of absolute risk reduction of VAP 
Absolute Risk Reduction (VPX vs SET) 
Total Net Benefit 
0.00 -£145* 
0.02 £0 
0.04 £208 
0.06 £385 
0.08 £561 
0.1 (base case value) £738 
0.12 £914 
0.14 £1,091 
0.16 £1,268 
0.18 £1,444 
0.2 £1,621 
* Negative values indicate that VPX is overall more costly than SET 
 
SDC Table 2. Total net benefit for different values of the additional cost of treating VAP 
Additional Cost of VAP 
Total Net Benefit 
£1450 £0 
£2000 £55 
£4000 £255 
£6000 £455 
£8000 £655 
£8829 (base case value) £738 
£10,000 £855 
£12,000 £1055 
£14,000 £1255 
£16,000 £1455 
£18,000 £1655 
£20,000 £1855 
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SDC Table 1. Total net benefit for different values of the acquisition cost of VPX 
Acquisition cost of VPX 
Total Net Benefit 
£50 £838 
£150 (base case value) £738 
£250 £638 
£350 £538 
£450 £438 
£550 £338 
£650 £238 
£750 £138 
£850 £38 
£888 £0 
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